Indivior Pharmaceuticals, Inc. (INDV)Healthcare | Drug Manufacturers - Specialty & Generic | North Chesterfield, United States | NasdaqGS
35.42 USD
-0.64
(-1.775%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 3:11 a.m. EDT
The immediate setup looks like a classic 'dead cat bounce' turning into a trend reversal. While the statistical forecast model is neutral, the options chain screams bullishness, with heavy positioning at the $39 resistance level for the next month. This aligns with the fundamental turnaround story: the company has erased a massive multi-year decline, posting a +198% gain last year and maintaining a healthy 26% profit margin. However, the balance sheet remains fragile with negative book value and operating cash flow, which keeps the long-term ceiling in check. With no dividend to rely on, the thesis rests entirely on the momentum of the recovery and the potential for the $40–$45 resistance to break, making this a high-conviction short-term trade rather than a buy-and-hold opportunity. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.095556 |
| AutoETS | 0.100145 |
| AutoARIMA | 0.100145 |
| AutoTheta | 0.133783 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 7.52 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.125 |
| Excess Kurtosis | -1.13 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2026-10-29 |
| Revenue per Share | 10.777 |
| Market Cap | 4,180,690,944 |
| Trailing P/E | 12.70 |
| Forward P/E | 7.25 |
| Beta | 1.18 |
| Profit Margins | 26.75% |
| Previous Name | Indivior PLC |
| Website | https://www.indivior.com |
As of Oct. 10, 2026, 3:11 a.m. EDT: Speculators are positioning aggressively for a breakout above $40, evidenced by massive open interest in October and November calls at the $39 strike compared to negligible put volume at those strikes. Conversely, deep out-of-the-money puts ($17.50, $25.00) show significant volume relative to their open interest, suggesting a hedge against a severe drop or a speculative bet on a crash. The skew is heavily bullish in the near term, with traders betting on a move toward the $45–$47 range seen in December options.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.4694376 |
| Address1 | 10,710 Midlothian Turnpike |
| Address2 | Suite 125 |
| All Time High | 42.81 |
| All Time Low | 1.75 |
| Ask | 45.42 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Daily Volume10 Day | 2,819,160 |
| Average Daily Volume3 Month | 2,225,850 |
| Average Volume | 2,225,850 |
| Average Volume10Days | 2,819,160 |
| Beta | 1.177 |
| Bid | 25.97 |
| Bid Size | 2 |
| Board Risk | 1 |
| Book Value | -1.763 |
| City | North Chesterfield |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 3 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 35.42 |
| Current Ratio | 0.835 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 36.245 |
| Day Low | 35.19 |
| Display Name | Indivior Pharmaceuticals |
| Dividend Date | 1,793,923,200 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,760,200 |
| Earnings Call Timestamp Start | 1,785,760,200 |
| Earnings Growth | 6.0 |
| Earnings Quarterly Growth | 5.778 |
| Earnings Timestamp | 1,785,760,200 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | 576,000,000 |
| Ebitda Margins | 0.43276 |
| Enterprise To Ebitda | 7.755 |
| Enterprise To Revenue | 3.356 |
| Enterprise Value | 4,467,043,328 |
| Eps Current Year | 4.40867 |
| Eps Forward | 4.88333 |
| Eps Trailing Twelve Months | 2.79 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,793,318,400 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 36.2905 |
| Fifty Day Average Change | -0.8705025 |
| Fifty Day Average Change Percent | -0.023987062 |
| Fifty Two Week Change Percent | 46.94376 |
| Fifty Two Week High | 42.81 |
| Fifty Two Week High Change | -7.390003 |
| Fifty Two Week High Change Percent | -0.17262329 |
| Fifty Two Week Low | 23.67 |
| Fifty Two Week Low Change | 11.749998 |
| Fifty Two Week Low Change Percent | 0.49640888 |
| Fifty Two Week Range | 23.67 - 42.81 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,419,863,400,000 |
| Float Shares | 109,461,200 |
| Forward Eps | 4.88333 |
| Forward P E | 7.2532473 |
| Free Cashflow | 86,500,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 827 |
| Fullday Change | -0.6400032 |
| Fullday Change Percent | -1.7748286 |
| Fullday Price | 35.42 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.85725 |
| Gross Profits | 1,140,999,936 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01802 |
| Held Percent Institutions | 1.0297799 |
| Implied Shares Outstanding | 118,031,934 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ipo Expected Date | 2,023-06-12 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. |
| Long Name | Indivior Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 4,180,690,944 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_277824630 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-14 |
| Net Income To Common | 356,000,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,234,985,791 |
| Number Of Analyst Opinions | 4 |
| Open | 36.09 |
| Operating Cashflow | -40,000,000 |
| Operating Margins | 0.46939 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Phone | 804 379 1040 |
| Prev Name | Indivior PLC |
| Previous Close | 36.06 |
| Price Eps Current Year | 8.034168 |
| Price Hint | 2 |
| Price To Book | -20.090754 |
| Price To Sales Trailing12 Months | 3.1410148 |
| Profit Margins | 0.26747 |
| Quick Ratio | 0.586 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.640003 |
| Regular Market Change Percent | -1.77483 |
| Regular Market Day High | 36.245 |
| Regular Market Day Low | 35.19 |
| Regular Market Day Range | 35.19 - 36.245 |
| Regular Market Open | 36.09 |
| Regular Market Previous Close | 36.06 |
| Regular Market Price | 35.42 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 1,819,746 |
| Return On Assets | 0.26397 |
| Revenue Growth | 0.136 |
| Revenue Per Share | 10.777 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 118,031,934 |
| Shares Percent Shares Out | 0.088199995 |
| Shares Short | 10,413,493 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 11,298,896 |
| Short Name | Indivior Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.10479999 |
| Short Ratio | 5.23 |
| Source Interval | 15 |
| State | VA |
| Symbol | INDV |
| Target High Price | 53.0 |
| Target Low Price | 43.0 |
| Target Mean Price | 49.0 |
| Target Median Price | 50.0 |
| Total Cash | 222,000,000 |
| Total Cash Per Share | 1.881 |
| Total Debt | 509,000,000 |
| Total Revenue | 1,331,000,064 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.79 |
| Trailing P E | 12.69534 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 35.73485 |
| Two Hundred Day Average Change | -0.31485367 |
| Two Hundred Day Average Change Percent | -0.008810829 |
| Type Disp | Equity |
| Volume | 1,819,746 |
| Website | https://www.indivior.com |
| Zip | 23,235 |